Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 11/20 | 1.00 |
| ▸ | CDK1 | P06493 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 11/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 11/20 | 1.00 |
| ▸ | GSK3A | P49840 | 10/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 10/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29913107 | 1.00 | GSK3B (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL27889519 | 0.81 | CCNB2 (0.68) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL27158570 | 0.80 | CCNB2 (0.67) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL7009747 | 0.78 | CCNB2 (0.63) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1780075 | 0.76 | CCNB2 (0.67) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL7922293 | 0.76 | CCNB2 (0.61) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1780850 | 0.76 | CCNB2 (0.71) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| Bromide SCHEMBL490800 | 0.75 | CCNB2 (0.97) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL7920467 | 0.74 | CCNB2 (0.59) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL490606 | 0.74 | CCNB2 (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1665809-A | Azaindoles | AVENTIS PHARMA LTD (GB) | 2005-09-07 | — | — | CN | claimed |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232383-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-8106050-B2 | 6-[1-(4-Chlorophenyl)-1-cyclopropyl][5H]pyrrolo[2,3-b]pyrazine; cyclin-dependent kinases and glycogen synthase kinase-3 inhibitor; antiproliferative, anticarcinogenic agent; neurodegenerative disorders; controlling the cell cycle apoptosis, neuronal functions, transcription and exocytosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-01-31 | — | — | US | disclosed |
| CN-100509811-C | Azaindoles | AVENTIS PHARMA LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| US-20080161312-A1 | Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-07-03 | — | — | US | disclosed |
| CN-100379734-C | Azaindoles | AVENTIS PHARMA LTD (GB) | 2008-04-09 | — | — | CN | disclosed |
| CN-1665809-A | Azaindoles | AVENTIS PHARMA LTD (GB) | 2005-09-07 | — | — | CN | disclosed |
| EP-1388541-A1 | Pyrrolopyrazines as kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161312-A1 | Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications | CDK2, PLK2, CDK5 | GSK3B 599/4885CCNB2 173/4885CDK1 39/4885 |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | GSK3B 491/4885CCNB2 4829/4885CDK1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.